BLIS Technologies Ltd
NZX:BLT
BLIS Technologies Ltd
NZX:BLT
Price:
0.015
NZD
7.14%
Market Closed
Market Cap:
NZ$19.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
BLIS Technologies Ltd
NZX:BLT
|
NZ |
|
Scandi Standard AB (publ)
STO:SCST
|
SE |
|
Sun Frontier Fudousan Co Ltd
TSE:8934
|
JP |
|
Huarong International Financial Holdings Ltd
HKEX:993
|
HK |
|
P
|
Philodrill Corp
XPHS:OV
|
PH |
|
Nexpe Participacoes SA
BOVESPA:NEXP3
|
BR |
|
R
|
Rama Steel Tubes Ltd
NSE:RAMASTEEL
|
IN |
|
Amano Corp
TSE:6436
|
JP |
|
S
|
STL Global Ltd
NSE:SGL
|
IN |
|
Z
|
Zicom Group Ltd
ASX:ZGL
|
AU |
|
G
|
Greenroc Mining PLC
LSE:GROC
|
UK |
|
S
|
Suedzucker AG
XBER:SZU
|
DE |
|
Carawine Resources Ltd
ASX:CWX
|
AU |
|
C
|
Core Molding Technologies Inc
F:XQN
|
US |
|
FJ Next Holdings Co Ltd
TSE:8935
|
JP |
|
N
|
National Healthcare Corp
AMEX:NHC
|
US |
|
V
|
VIVA Biotech Holdings
HKEX:1873
|
CN |
Multiples-Based Value
The Multiples-Based Value of one
BLT
stock under the Base Case scenario is
hidden
NZD.
Compared to the current market price of 0.015 NZD,
BLIS Technologies Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BLT Multiples-Based Value
LOCKED
Multiples Across Competitors
BLT Competitors Multiples
BLIS Technologies Ltd Competitors
BLIS Technologies Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NZ |
|
BLIS Technologies Ltd
NZX:BLT
|
19.2m NZD | 1.3 | 18.7 | 9.5 | 9.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 13.4 | 42.4 | 28.6 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD | 6.2 | 21.6 | 15 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.3 | 30.3 | 16.7 | 23.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.2 | 20.9 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.2B USD | 2.5 | 20.4 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.4B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
